perkinelmer, inc. · 2 safe harbor statement • this document shows current intentions regarding...
TRANSCRIPT
1
HUMAN HEALTH • ENVIRONMENTAL HEALTH
PerkinElmer, Inc.
Karen Madden, Ph.D.
President
Informatics: Helping our Customers Answer Critical Questions
2
Safe Harbor Statement
• This document shows current intentions regarding product features, behavior,
schedules and support; these intentions may change without notice as we respond to customer requirements.
• Any unreleased products, services or features referenced herein are not currently
available and may not be delivered on time or at all. Customers who purchase
PerkinElmer informatics applications should make their purchase decisions based
upon products, features, and services that are currently available.
3
Improving the health and safety of people and the environment
Environmental Health Human Health
$2.4
BILLION
IN SALES
20%
EBITDA
8,000
EMPLOYEES
4
IMPROVING THE HEALTH AND SAFETY
OF PEOPLE AND THE ENVIRONMENT
2016 STRATEGIC PRIORITIES
DRIVING INNOVATION FOCUSING ON
CUSTOMERS
OPERATIONAL
EFFECTIVENESS
O U R M I S S I O N __________
5
● Is the water clean?
● Is my food safe?
● How healthy is the air I breathe?
● Is my baby healthy?
● Is the blood supply safe?
● Are drug candidates showing efficacy?
Environmental Health Human Health
At PerkinElmer We Provide Answers
6
DETECTION IMAGING INFORMATICS SERVICE
Our Capabilities
7
75% Of revenue
From Products with
Market Position
Top 3
Strong portfolio with
leading positions FOCUSED ON CATEGORY
LEADERSHIP
8
SOLVING CUSTOMER NEEDS
H E A L T H I E R B A B I E S
worldwide to date for a variety
of life-threatening diseases
Our newborn screening
technologies have
450M BABIES
H E L P E D S C R E E N
9
SOLVING CUSTOMER NEEDS
2.25B
reducing the risk of contaminants
Last year, our detection solutions are
used to analyze approximately
AIR, WATER & SOIL
SAMPLES,
A C L E A N E R A N D S A F E R E N V I R O N M E N T
10
SOLVING CUSTOMER NEEDS
Our technologies and
expertise were instrumental
in the development of...
M O R E E F F E C T I V E M E D I C I N E S
22 DRUGS
of the
NEWEST THERAPUTIC
11
Pharma R&D Reality…
R&D activity and spend
increasing
NME Approvals
decreasing
The estimated average pre-tax industry cost per new prescription drug approval (inclusive of failures
and capital costs) is: $2,558M
12
Moore’s Law
What’s going on?
13
Eroom’s Law
• The ‘Better than the Beatles’ problem, which is our tendency to compete against our greatest hits of the past. Consider for example, how hard it would be to come up with a successful pop song if any new song had to be better than the Beatles. How difficult it would be to create a successor candidate for a successful drug like Lipitor? We are tackling harder problems….
• The ‘Cautious Regulator’ problem is the progressive lowering of risk tolerance that raises the bar on safety for new drugs, which makes R&D both costlier and harder.
• The ‘Throw money at it’ tendency is the tendency to just keep pouring more money and resources into a research project or widely held theory until something sticks. It is like throwing good money after bad.
• The ‘Basic Research-Brute Force’ bias, which is the tendency to overestimate the probability that advances in basic research and large scale screening processes will show a molecule safe and effective in clinical trials.
Personalized Medicine
More Data, Evidence
& Monitoring
Faster Insight to Action
Translational Research
Diagnosing the decline in pharmaceutical R&D efficiency Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington
Nature Reviews Drug Discovery 11, 191-200 (March 2012)
14
Dementia
40M+; set to triple by 2050
Treating and caring
for people with
dementia currently
costs the world more
than US$ 604 billion
per year
Diabetes
400M+ compared to 100M in 1980
Can lead to heart
attack, stroke,
kidney failure, leg
amputation, vision
loss and nerve
damage
Infectious Disease
58 countries and territories reporting
Increase in Guillain-
Barré syndrome as
well as an increase in
babies born with
microcephaly
Cancer
14M+ new cases; 8M deaths WW
Declared War on
Cancer 30 years ago
and now again a
call to action
Science and Research is hard!
15
Big Questions & Answers Requires Big Data
Genomics
● 3 Billion bases per human genome
● 25,000 genes, millions of variants
● Up to 1TB of data per sample
● 1000, 100,000, Million Genome project
● High Volume and Velocity
Imaging
● Millions of compounds / Functional Screening
● Thousands of cells per well,
● Billions of measurements per run
● High degree of automation
● Extremely high Volume and Velocity
Outcomes
● 200,000 registered clinical trials
● Millions of patients, doctor visits, and samples
● Information encoded in unstructured patient records
● Shifting towards complete genomic analysis of patients
● High Volume and Variety
16
Another Challenge (Opportunity): One size does not fit all
17
Off-shore research &
clinical trials
CROs
Not invented here
anymore
Collaborators
Local labs
Consolidated
Centralized R&D
Growing middle class
and access to
healthcare
Emerging Markets
Another Challenge (Opportunity): Distributed Research & Development
Mainframe
Centralized
Concrete
Isolated
Secretive
OLD NEW
Cloud
Distributed
Virtual
Social
Public
18
Transactional Systems, Data Silos, Discovery & Access Restrictions
Isolation
Distributed Research Models Limited Sharing and Collaboration
Collaboration
On-premise Data Centers, Expensive and Complex
Infrastructure
Patients, Assays, Tissues, Organisms, Proteins, Genes,
Variety
100,000s of samples, 100s of GB per Day per Experiment
Volume
Structured vs. Unstructured Data, How to make Sense of the Data
Complexity
Many Informatics Challenges (Opportunities) in Life Science
19
New Informatics for New Science
The pace of life science data generation and the complexity of the
generated data is outperforming existing informatics solutions
20
Collaboration
Data Analysis
&
Visualization
Scientific
Smarts
Data
Integration
Scientific Informatics Platform
E-Notebook, Signals and cloud
platform to support scientific
research
Collaboration
Scientific intelligence, modeling
& workflows
Scientific Smarts
Best in class data analytics,
visualization & workflows
Data Analysis & Visualization
Unified access to all your
relevant data sources
Data Integration
PerkinElmer Informatics: Big Data Prescription for R&D
Supporting new speed of science
21 21
Lets you access &
assemble all
of your data
Right Data
Right Time
Right Person
“If you can establish a common visual language for data, you can radically upgrade the use of that data to drive decision-making and action.”
Thomas H. Davenport Harvard Business Review blog, 2013
World-renowned author & business analytics expert
22
PKI Columbus Image Acquisition
Spotfire Analytics & Visualization
On-Premise Columbus
Signals for Screening
Servers 1 Server, 16 CPUs, 32GB
4000 Node Cluster
1 Plate 2 Days 3 Minutes
100 Plates 200 Days 30 Minutes
High Content Screening: Signals for Imaging
(Jens Hoefkens)
• Data ingestion, curation • Search, retrieval • Multi-parametric analysis • Applications (workflows)
Data Import and Aggregation
Spotfire Templates
High Content Profiler
Curve Fitting
SAR
Real-time Analytics
Alerts, Reports, Publish, Collaborate
Automated Workflow
23
Quantitative Pathology
(Trent Norris)
24
Clinical & Real World Evidence
(Jamie Powers)
Source: Adapted from McKinsey Practice Perspectives on RWD
25
Signals Perspectives (Attivio): Get a 360° View of Available Data
(Brendon Kellner)
A
Enrichment
Classify
Provision Ingest
Semi structured
Unstructured
Flat file (ad-hoc or fileshare
26
Gartner Hype Cycle Life Sciences (2016) What’s on the horizon that we need to pay attention to…
Source: Gartner (July 2016)
Key INF Focus Areas
Adjacent Areas
PerkinElmer Uniquely Positioned to Deliver Future Solutions
27
Redefining Scientific Analytics Solutions: High Content Screening
“HC Profiler simplifies and standardizes high content analysis by following a logical workflow from quality control to feature and ultimately hit selection. PerkinElmer has leveraged Spotfire’s rich data visualization capabilities and underlying R architecture to provide the necessary analytical tools for HCS, all in one convenient package."
Top Pharma
Capture & Collaboration Analytics, Insight
Ideation Detection/Data File Analysis
Intensity Texture Morphology
• Complete instrument to insight HCS solution • Delivering greater customer value
The right gene
The right compound
Many locations Hundreds of studies Millions of cells Bill ions of features
28
High Content Screening: Operetta CLS & Signals for Imaging
What?
Why?
• New mid-range high content screening (HCS) platform: successor to existing Operetta
with superior image quality and flexibility
• Used in drug screening to identify most relevant drug candidates prior to costly
preclinical and clinical phase
• Signals is a big data management, aggregation, and analysis platform supporting the
complete research and precision medicine workflow
• Advanced technology leading to superior results with complex models
• Affordable and accessible HCS: optical quality and flexibility of high-end Opera
Phenix (but lower throughput) at mid-range price
40x Air 40x Water = 4x brighter
29
by
Analytics &
IoT Instrumentation
Information
Services
Scientific
Services Compliance
• Leading Scientific
Laboratory Solutions
provider (OneSource)
• #1 in Data Visualization
Software Solutions
• Serving all of the 20 Largest
Pharma Companies
Pharma /
BioPharma
Services
Services & Informatics
>95 customer programs
across
>350 sites in over 20
countries
>500,000 MV ASSETS SERVICED
$475M+ Services revenue
“By leveraging analytics across the IoT spectrum and connecting previously disconnected data elements from the exisitng instrumentation, performance can be better monitored and new insights can
be generated” –Gartner Life Science Hype Cycle
IoT
30
Towards a Scientific Drug Discovery Informatics Platform Bringing the Pieces Together
Customer Needs
Utilizes cloud and mobile technologies
Simplifies IT environment
Integrates best in class applications
Provide cohesive
user experience
Lowers TCO
Supports distributed research
Improves data access / integration
Increases R&D productivity
Research ELN
Inventory Registration
Assay Data Management
LIMS Dev ELN
Image Data Management
SDMS CDS Predictive Modeling
EDC
Scientific Apps
Chemistry Image
Analysis Clinical Apps
Third-Party Apps
Services
Cloud
Analytics & Visualization
Se
arc
h
Da
ta
Inte
gra
tio
n
External Partners
/ Collaborators
Internal
Users
HCProfiler CDR, RBM, RWE
IoT
E L N i s C e n t r a l F u n c t i o n a l i t y
“These systems can reduce IT complexity and change the high IT cost models…can also enable rapid set-up with collaborative partners and facilitate drug discovery and
external partnering strategies for external innovation” –Gartner Life Science Hype Cycle
31
W E E M P O W E R S C I E N T I S T S T O M A K E B E T T E R D E C I S O N S
32
Turning the Corner on Eroom’s Law?
33
A parting thought….
“One of the very few silver linings about me getting sick is that Reed’s gotten
to spend a lot of time studying with some very good doctors… I think the
biggest innovations of the twenty-first century will be the intersection of biology and technology. A new era is beginning, just like the digital one when I was his age.”
-Steve Jobs
34
Driving INNOVATION to provide INSIGHTS
that make an IMPACT